Medicenna Therapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Bloor St W Fl 7, Toronto, Ontario, M4W...Phone Number
(416) 648-5555Website
www.medicenna.comRevenue
<$5 MillionStock Symbol
MDNAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Medicenna Therapeutics
Located in Toronto, Canada, Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines for the treatment of a broad range of cancers.Explore more
Medicenna Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medicenna Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Medicenna Therapeutics
Website visits: Recent activity has been detected on your website
Check if Medicenna Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Medicenna Therapeutics has new funding data
Medicenna Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Medicenna Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Medicenna Therapeutics launches new products
Earning: See what the market has to say on Medicenna Therapeutics recently announced quarterly report
Check out if Medicenna Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Medicenna Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Medicenna Therapeutics
Compare insights from companies similar to Medicenna Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Medicenna Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Medicenna Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Medicenna Therapeutics.
Medicenna Therapeutics financials insights
Gather financial insights about Medicenna Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$798K
2024
Share Placement
$14.6M
2026
Stock/Share Issuance
$254K
Medicenna Therapeutics Tech Stack
A closer look at the technologies used by Medicenna Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Medicenna Therapeutics News & Media
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16,Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conferenceMedicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitorsMedicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 active granted patents and applications New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 active granted patents and app
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Medicenna Therapeutics
Sign Up For FreeTo access detailed company insights
Located in Toronto, Canada, Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Superkines for the treatment of a broad range of cancers.... Read More
